FIVE THINGS TO KNOW ABOUT... The use of opioids for dyspnea in advanced disease

Gallagher, Romayne
July 2011
CMAJ: Canadian Medical Association Journal;7/12/2011, Vol. 183 Issue 10, p1170
Academic Journal
The article offers information about the use of opioids in treating dyspnea in advanced disease. It states that opioids are highly used for treating dyspnea refractory to disease-specific therapy in advanced disease. It notes that opiods with active metabolites can accumulate in frail older patients which can cause drowsiness, confusion, and delirium.


Related Articles

  • Conditioned place aversion is a highly sensitive index of acute opioid dependence and withdrawal. Azar, Marc R.; Jones, Byron C.; Schulteis, Gery // Psychopharmacology;2003, Vol. 170 Issue 1, p42 

    Rationale. Conditioned place aversion (CPA) is known to be a sensitive measure of the aversive motivational state produced by opioid withdrawal in rats made chronically dependent on opioids. Objective. The purpose of the present study was to examine the sensitivity of the CPA model in detecting...

  • Prescription drug abuse tied to increased risk of teen suicide.  // Arab American News;8/20/2016, Vol. 32 Issue 1593, p20 

    The article reports on the increase risk of suicide around the world which teens abuse prescription of drugs where some of the used prescription drugs for non-medical purpose.

  • Carbamazepine overdose.  // Reactions Weekly;12/16/2006, Issue 1132, p5 

    This article presents a case study involving a woman who developed increasing drowsiness, coma and subsequent delirium after an overdose of carbamazepine. An hour after ingesting 200 controlled-release tablets of carbamazepine, the woman was brought to an emergency department. She underwent...

  • Agitated Terminal Delirium and Association with Partial Opioid Substitution and Hydration. Morita, Tatsuya; You Tei; Inoue, Satoshi // Journal of Palliative Medicine;Aug2003, Vol. 6 Issue 4, p557 

    Background: Delirium is often a distressing symptom for both patients and their families, and its prevention is important. The primary aim of this study was to clarify the effects of partial opioid substitution and hydration on the occurrence of agitated delirium in the final stage of cancer....

  • Baclofen/opioid analgesics/prednisone.  // Reactions Weekly;Jan2015, Vol. 1535 Issue 1, p47 

    The article presents a case study of a 68-year-old woman who developed delirium after receiving prednisone, baclofen, and opioid analgesic treatment.

  • Opioids linked to longitudinal risk of delirium in cancer patients.  // Reactions Weekly;7/21/2007, Issue 1161, p4 

    The article discusses research being done on opioids and delirium. It references a study by J.-D. Gaudreau et al published in the June 1, 2007 issue of "Cancer 09." The study suggests that exposure to opioid analgesics is associated with an increased longitudinal risk of delirium. A prospective,...

  • Behavioral assessment of temporal summation in the rat: sensitivity to sex, opioids and modulation by NMDA receptor antagonists. Lomas, Lisa M.; Picker, Mitchell J. // Psychopharmacology;Jun2005, Vol. 180 Issue 1, p84 

    Presents a study which discussed whether repeated representations of a thermal nociceptive stimulus produces systematic increases in nociceptive sensitivity in rats. Uses of opioids; List of the parameters of the procedure that was used to assess temporal summation magnitude; Optimal time...

  • Autoantibodies against opioid or glutamate receptors are associated with changes in morphine reward and physical dependence in mice. Capone, Francesca; Adriani, Walter; Shumilina, Maria; Izykenova, Galina; Granstrem, Oleg; Dambinova, Svetlana; Laviola, Giovanni // Psychopharmacology;May2008, Vol. 197 Issue 4, p535 

    Possible interactions between nervous and immune systems during opioid addiction remain elusive. Recombinant μ–δ opioid receptors (MDOR) and the glutamate receptor 1 (GluR1) subunit of amino-3-hydroxy-5-methyl-4-isoxazole propionic acid glutamate receptors are involved in acute and...

  • Involvement of the endogenous opioid system in the psychopharmacological actions of ethanol: the role of acetaldehyde. Font, Laura; Luján, Miguel Á.; Pastor, Raúl // Frontiers in Behavioral Neuroscience;Jul2013, Vol. 7, p1 

    Significant evidence implicates the endogenous opioid system (EOS) (opioid peptides and receptors) in the mechanisms underlying the psychopharmacological effects of ethanol. Ethanol modulates opioidergic signaling and function at different levels, including biosynthesis, release, and degradation...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics